Blueprint Medicines Corp (NASDAQ: BPMC)’s stock price has decreased by -1.55 compared to its previous closing price of 84.40. However, the company has seen a -3.38% decrease in its stock price over the last five trading sessions. zacks.com reported 2024-10-24 that New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
Is It Worth Investing in Blueprint Medicines Corp (NASDAQ: BPMC) Right Now?
BPMC has 36-month beta value of 0.59. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BPMC is 62.20M, and currently, short sellers hold a 5.67% ratio of that float. The average trading volume of BPMC on October 25, 2024 was 651.23K shares.
BPMC’s Market Performance
BPMC stock saw a decrease of -3.38% in the past week, with a monthly decline of -4.49% and a quarterly a decrease of -25.94%. The volatility ratio for the week is 3.29%, and the volatility levels for the last 30 days are 3.14% for Blueprint Medicines Corp (BPMC). The simple moving average for the last 20 days is -5.65% for BPMC stock, with a simple moving average of -12.33% for the last 200 days.
Analysts’ Opinion of BPMC
Stephens, on the other hand, stated in their research note that they expect to see BPMC reach a price target of $140. The rating they have provided for BPMC stocks is “Overweight” according to the report published on May 14th, 2024.
Leerink Partners gave a rating of “Market Perform” to BPMC, setting the target price at $97 in the report published on May 06th of the current year.
BPMC Trading at -7.44% from the 50-Day Moving Average
After a stumble in the market that brought BPMC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.84% of loss for the given period.
Volatility was left at 3.14%, however, over the last 30 days, the volatility rate increased by 3.29%, as shares sank -6.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.00% lower at present.
During the last 5 trading sessions, BPMC fell by -3.38%, which changed the moving average for the period of 200-days by +0.13% in comparison to the 20-day moving average, which settled at $88.07. In addition, Blueprint Medicines Corp saw -9.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BPMC starting from Namouni Fouad, who sale 3,633 shares at the price of $89.32 back on Oct 03 ’24. After this action, Namouni Fouad now owns 69,070 shares of Blueprint Medicines Corp, valued at $324,500 using the latest closing price.
Albers Jeffrey W., the Director of Blueprint Medicines Corp, sale 19,702 shares at $85.57 during a trade that took place back on Sep 09 ’24, which means that Albers Jeffrey W. is holding 157,557 shares at $1,685,891 based on the most recent closing price.
Stock Fundamentals for BPMC
Current profitability levels for the company are sitting at:
- -0.98 for the present operating margin
- 0.93 for the gross margin
The net margin for Blueprint Medicines Corp stands at -0.57. The total capital return value is set at -0.37. Equity return is now at value -65.09, with -17.79 for asset returns.
Based on Blueprint Medicines Corp (BPMC), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -0.5. The debt to equity ratio resting at 2.08. The interest coverage ratio of the stock is -8.26.
Currently, EBITDA for the company is -474.61 million with net debt to EBITDA at -1.98. When we switch over and look at the enterprise to sales, we see a ratio of 16.4. The receivables turnover for the company is 4.27for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.71.
Conclusion
To put it simply, Blueprint Medicines Corp (BPMC) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
